CONQUEST
4.4.2024 12:19:30 CEST | Business Wire | Press release
Conquest enters the Finnish renewable power market with the acquisition from BHM Renewables (a BHM group company) of a 182MW onshore wind portfolio developed by Winda Energy and the implementation of a broader strategic partnership towards further extensions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240404783244/en/
Shutterstock, Wind Portfolio in Finland
Conquest, a fund manager focusing on the infrastructures of the energy transition in Europe, through its fund Conquest Infrastructure SLP – Sustainable 2, has completed the concomitant acquisitions of two wind farms developed by Winda Energy, the Finnish renewable energy developer majority-owned by Czech BHM Renewables, part of the investment firm BHM group. The two onshore wind projects have a combined capacity of 182MW. Furthermore, the cooperation encompasses additional onshore wind projects totalling 500MW.
The transaction allows Conquest to expand its renewable power platform and its footprint in the Nordics market, while maintaining a well-balanced and diversified approach towards investments targeted to the energy transition in Europe. The transaction represents an expected phased total investment of approximately 1 billion euros, to be gradually deployed between 2024 and 2028, offering a fully green investment in one of Europe’s most stable and robust economies.
The first two wind projects are at an advanced stage of development, with the first 182MW expected to reach ready-to-build by Q4 2024 and the rest expected to reach the same stage by Q4 2025. Winda Energy Oy will complete the development and manage the construction with expected start dates of commercial operations ranging from 2026 to 2028 for the portfolio.
Frederic Palanque, Founder and Managing Director of Conquest said: “Conquest is thrilled to enter, in partnership with Winda Energy, in sustainable real assets in a market recognized for its robust renewable energy fundamentals and its ambitious net zero roadmap.”
“We are happy to cooperate with Conquest, a dynamic and reliable partner on our growth journey. The transaction secures the completion of some of our flagship projects over the next years, enabling us to extend our contribution to Finland’s green energy transition.”, says Tuomas Hooli, CEO of Winda Energy.
Michal Prause, Associate Partner at BHM Renewables, said: “We are extremely pleased with the outcome of the transaction, reflecting the deep development skills, which our affiliate Winda has been demonstrating on the Finnish renewable power market over the years. We are looking forward to the strategic partnership with the highly professional asset management and investment teams of Conquest.”
ABOUT
Conquest
Established in 2012, Conquest is an alternative asset management firm invested in sustainable and long-term value stemming from European infrastructures. Conquest invests in and operates long-life, high- quality assets and businesses on behalf of its clients, which range from large institutional investors to single-family offices. With a team of 20 collaborators, based in Dublin and Paris, the firm manages assets worth circa 500 million euros and 25 investments across Europe.
BHM group
BHM group is a rapidly expending European investment firm that manages dozens of European companies in Europe. In the energy sector, BHM group is focused on investments in renewable energy sources, with an emphasis on wind and solar energy, and is active in six countries in Central Europe and Scandinavia. Due to its extensive experience and many successful projects, BHM group companies can provide comprehensive services, encompassing development, construction, and operation. BHM group focuses on long-term and stable partnerships that take into account healthy economic growth and are in line with internationally recognized standards of social responsibility and sustainability.
Winda Energy
Winda Energy Oy is a leading Finnish renewable energy project developer with its current development portfolio consisting of 3 GW of onshore wind and 1 GW of solar PV across Finland. Winda Energy has extensive experience in the renewable sector and takes projects from their initial design to the end of construction, most recently completing the construction of 200 MW of onshore wind in 2023. Winda Energy is majority owned by BHM group.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240404783244/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom